Wedbush Issues Optimistic Outlook for TSE:FRX Earnings

Fennec Pharmaceuticals Inc. (TSE:FRX) – Wedbush raised their Q3 2025 earnings per share (EPS) estimates for shares of Fennec Pharmaceuticals in a research note issued on Sunday, December 22nd. Wedbush analyst D. Nierengarten now anticipates that the biopharmaceutical company will post earnings of $0.56 per share for the quarter, up from their previous estimate of $0.46. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.60 per share. Wedbush also issued estimates for Fennec Pharmaceuticals’ FY2026 earnings at $3.03 EPS and FY2027 earnings at $4.06 EPS.

Separately, Stephens raised shares of Fennec Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 18th.

Fennec Pharmaceuticals Stock Up 0.2 %

Shares of TSE:FRX opened at C$8.93 on Tuesday. The company has a 50 day moving average of C$7.19 and a 200-day moving average of C$7.67. Fennec Pharmaceuticals has a one year low of C$5.65 and a one year high of C$15.43. The stock has a market cap of C$244.32 million, a price-to-earnings ratio of 89.30 and a beta of 0.25. The company has a debt-to-equity ratio of 1,040.68, a current ratio of 8.02 and a quick ratio of 10.17.

Insider Activity at Fennec Pharmaceuticals

In other Fennec Pharmaceuticals news, Senior Officer Robert Christopher Andrade acquired 15,816 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The shares were acquired at an average price of C$3.43 per share, with a total value of C$54,248.88. Also, Director Rostislav Christov Raykov bought 25,000 shares of the firm’s stock in a transaction on Friday, December 20th. The stock was acquired at an average cost of C$3.87 per share, with a total value of C$96,840.00. Over the last quarter, insiders purchased 41,612 shares of company stock worth $157,868. 16.20% of the stock is owned by insiders.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.